F10 and breast cancer: We are currently studying Rivaroxaban, a DOAC licensed for the prophylaxis and treatment of VTE that is an inhibitor of Factor Xa, thereby inhibiting the TF-Factor VIIa-Factor Xa complex, in a Phase II trial of early breast cancer patients (TIP Trial, EudraCT No.: 2014–004909-33) [45].